{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:42:53Z","timestamp":1770140573052,"version":"3.49.0"},"reference-count":87,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Cardiovascular disease (CVD) in heterozygous familial hypercholesterolemia (HeFH), the most frequent monogenic disorder of human metabolism, is largely driven by low-density lipoprotein (LDL) cholesterol concentrations. Since the CVD rate differs considerably in this population, beyond the lifetime LDL cholesterol vascular accumulation, other classical risk factors are involved in the high cardiovascular risk of HeFH. Among other lipoprotein disturbances, alterations in the phenotype and functionality of high-density lipoproteins (HDL) have been described in HeFH patients, contributing to the presence and severity of CVD. In fact, HDL are the first defensive barrier against the burden of high LDL cholesterol levels owing to their contribution to reverse cholesterol transport as well as their antioxidant and anti-inflammatory properties, among others. In this context, the present narrative review aimed to focus on quantitative and qualitative abnormalities in HDL particles in HeFH, encompassing metabolic, genetic and epigenetic aspects.<\/jats:p>","DOI":"10.3390\/biomedicines9070810","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T22:25:31Z","timestamp":1626215131000},"page":"810","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Familial Hypercholesterolemia: Do HDL Play a Role?"],"prefix":"10.3390","volume":"9","author":[{"given":"Juan","family":"Pedro-Botet","sequence":"first","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Campus Universitari Mar, 08003 Barcelona, Spain"},{"name":"Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisenda","family":"Climent","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Campus Universitari Mar, 08003 Barcelona, Spain"},{"name":"Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5411-364X","authenticated-orcid":false,"given":"David","family":"Benaiges","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Campus Universitari Mar, 08003 Barcelona, Spain"},{"name":"Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJM197606172942509","article-title":"Familial hypercholesterolemia: A genetic defect in the low-density lipoprotein receptor","volume":"294","author":"Bleich","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0022-2275(20)42605-7","article-title":"Familial defective apolipoprotein B-100: A mutation of apolipoprotein B that causes hypercholesterolemia","volume":"31","author":"Innerarity","year":"1990","journal-title":"J. Lipid Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1210\/jc.2015-3874","article-title":"The p.Leu167del Mutation in APOE gene causes autosomal dominant hypercholesterolemia by down-regulation of LDL receptor expression in hepatocytes","volume":"101","author":"Cenarro","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: Consequences for coronary artery disease and all-cause mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2018.04.040","article-title":"Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register","volume":"274","author":"Humphries","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.atherosclerosis.2019.02.003","article-title":"Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia","volume":"284","author":"Laclaustra","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/01.CIR.92.3.290","article-title":"Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation","volume":"92","author":"Ferrieres","year":"1995","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1161\/01.ATV.0000177811.14176.2b","article-title":"Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low density lipoprotein receptor gene mutation","volume":"25","author":"Civeira","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","article-title":"The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: Data in 2400 patients","volume":"25","author":"Jansen","year":"2004","journal-title":"J. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: A consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)","volume":"135","author":"Alonso","year":"2017","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/MOL.0000000000000519","article-title":"Predicting cardiovascular disease in familial hypercholesterolemia","volume":"29","author":"Paquette","year":"2018","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacl.2018.10.012","article-title":"Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis","volume":"13","author":"Akioyamen","year":"2019","journal-title":"J. Clin. Lipidol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1093\/eurheartj\/ehx274","article-title":"HDL cholesterol concentration or HDL function: Which matters?","volume":"38","author":"Barter","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrcardio.2017.115","article-title":"HDL and atherosclerotic cardiovascular disease: Genetic insights into complex biology","volume":"15","author":"Rosenson","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_19","first-page":"485","article-title":"Recherches sur les phosphoaminolipides du s\u00e9rum sanguin. Nature des phospholipides li\u00e9s aux albumines du s\u00e9rum de cheval \u00e0 l\u2019\u00e9tat de cenapses acido-pr\u00e9cipitables","volume":"11","author":"Macheboeuf","year":"1929","journal-title":"Bull. Soc. Chim. Biol. (Paris)"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Incidence of coronary heart disease and lipo-protein cholesterol levels. The Framingham Study","volume":"256","author":"Castelli","year":"1986","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Emerging Risk Factors Collaboration, Di Angelantonio, E., Sarwar, N., Perry, P., Kaptog, S., Ray, K.K., Thompson, A., Wood, A.M., Lewington, S., and Sattar, N. (2009). Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 302, 1993\u20132000.","DOI":"10.1001\/jama.2009.1619"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jacc.2012.03.060","article-title":"High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"60","author":"Mackey","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJM198401123100216","article-title":"HDL cholesterol in familial hypercholesterolemia","volume":"310","author":"Seftel","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM198308043090507","article-title":"Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia","volume":"309","author":"Goldstein","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/euhj.2000.2408","article-title":"Importance of HDL cholesterol levels and the total\/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercho-lesterolaemia","volume":"22","author":"Real","year":"2001","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1161\/01.ATV.0000218507.95149.42","article-title":"Influence of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia","volume":"26","author":"Junyent","year":"2006","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Khoury, E., Brisson, D., Roy, N., Tremblay, G., and Gaudet, D. (2020). Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia. J. Clin. Med., 10.","DOI":"10.3390\/jcm10010064"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/0026-0495(93)90138-E","article-title":"Insulin sensitivity in familial hypercholesterolemia","volume":"42","author":"Galvan","year":"1993","journal-title":"Metabolism"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/01.CIR.97.9.871","article-title":"Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene","volume":"97","author":"Gaudet","year":"1998","journal-title":"Circulation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100062","DOI":"10.1016\/j.jlr.2021.100062","article-title":"Lipoprotein metabolism in familial hypercholesterolemia","volume":"62","author":"Chemello","year":"2021","journal-title":"J. Lipid Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0022-2275(20)33394-0","article-title":"Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: A stable isotope study","volume":"40","author":"Ouguerram","year":"1999","journal-title":"J. Lipid Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.atherosclerosis.2006.02.023","article-title":"Association of heterozygous familial hypercholesterolemia with smaller HDL particle size","volume":"190","author":"Hogue","year":"2007","journal-title":"Atherosclerosis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/ATVBAHA.111.227181","article-title":"Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia","volume":"31","author":"Bellanger","year":"2011","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.11.035","article-title":"Altered HDL remodeling and functionality in familial hypercholesterolemia","volume":"71","author":"Plana","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/01.ATV.7.4.401","article-title":"Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia","volume":"7","author":"Gibson","year":"1987","journal-title":"Arteriosclerosi."},{"key":"ref_36","first-page":"50","article-title":"HDL cholesterol levels in patients with molecularly defined familial hypercholesterole-mia","volume":"32","author":"Miltiadous","year":"2002","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1194\/jlr.P061598","article-title":"ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia","volume":"57","author":"Cubedo","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","article-title":"Dysfunctional HDL and atherosclerotic cardiovascular disease","volume":"13","author":"Rosenson","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.plipres.2017.05.001","article-title":"HDL abnormalities in familial hypercholesterolemia: Focus on biological functions","volume":"67","author":"Ganjali","year":"2017","journal-title":"Prog. Lipid Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Wong, N.K.P., Nicholls, S.J., Tan, J.T.M., and Bursill, C.A. (2018). The role of high-density lipoproteins in diabetes and its vascular complications. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061680"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jacc.2017.05.018","article-title":"Detrimental effect of hypercholesterolemia on high-density lipoprotein particle remodeling in pigs","volume":"70","author":"Cubedo","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11883-021-00928-1","article-title":"Reverse cholesterol transport dysfunction is a feature of familial hypercho-lesterolemia","volume":"23","author":"Rotllan","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.metabol.2013.02.008","article-title":"Transfer of lipids to high-density lipoprotein (HDL) is altered in patients with familial hypercholesterolemia","volume":"62","author":"Martinez","year":"2013","journal-title":"Metabolism"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/eci.12643","article-title":"Familial hypercholesterolaemia: Cholesterol efflux and coronary disease","volume":"46","author":"Versmissen","year":"2016","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/CIRCRESAHA.119.316424","article-title":"LDL receptor regulates the reverse transport of macrophage-derived unesterified cholesterol via concerted action of the HDL-LDL axis: Insight from mouse models","volume":"127","author":"Cedo","year":"2020","journal-title":"Circ. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1194\/jlr.M024141","article-title":"Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia","volume":"53","author":"Orsoni","year":"2012","journal-title":"J. Lipid Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/112_2020_26","article-title":"Inflammatory biomarkers for cardiovascular risk stratification in familial hypercholesterolemia","volume":"177","author":"Bahrami","year":"2020","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cccn.2005.03.050","article-title":"Altered composition of HDL3 in FH subjects causing a HDL subfraction with less atheroprotective function","volume":"359","author":"Balstad","year":"2005","journal-title":"Clin. Chim. Acta"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jacl.2015.10.006","article-title":"Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis","volume":"10","author":"Hussein","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jacl.2018.08.007","article-title":"Feasibility of a plasma bioassay to assess oxidative protection of low-density lipoproteins by high-density lipoproteins","volume":"12","author":"Swertfeger","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/iub.588","article-title":"Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation","volume":"64","author":"Hine","year":"2011","journal-title":"IUBMB Life"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2016.05.023","article-title":"Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia","volume":"250","author":"Silva","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1194\/jlr.P088997","article-title":"Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol","volume":"60","author":"Gruppen","year":"2019","journal-title":"J. Lipid Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1194\/jlr.M400052-JLR200","article-title":"Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia","volume":"46","author":"Roest","year":"2005","journal-title":"J. Lipid Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1590\/1678-4685-gmb-2016-0287","article-title":"Decreased serum PON1 arylesterase activity in familial hypercholesterolemia patients with a mutated LDLR gene","volume":"41","author":"Idrees","year":"2018","journal-title":"Genet. Mol. Biol."},{"key":"ref_57","first-page":"667","article-title":"MicroRNAs in lipoprotein and lipid metabolism: From biological function to clinical ap-plication","volume":"55","author":"Bouchard","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2217\/epi-2018-0161","article-title":"Human high-density lipoprotein microtranscriptome is unique and suggests an extended role in lipid metabolism","volume":"11","author":"Guay","year":"2019","journal-title":"Epigenomics"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncb2210","article-title":"MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins","volume":"13","author":"Vickers","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1042\/CS20171121","article-title":"Circulating miR-200c is up-regulated in paediatric patients with familial hypercholesterolaemia and correlates with miR-33a\/b levels: Implication of a ZEB1-dependent mechanism","volume":"131","author":"Martino","year":"2017","journal-title":"Clin. Sci. (Lond)"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Scicali, R., Di Pino, A., Pavanello, C., Ossoli, A., Strazzella, A., Alberti, A., Di Mauro, S., Scamporrino, A., Urbano, F., and Filippello, A. (2019). Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-56857-2"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Prats-Uribe, A., Sayols-Baixeras, S., Fern\u00e1ndez-Sanl\u00e9s, A., Subirana, I., Carreras-Torres, R., Vilahur, G., Civeira, F., Marrugat, J., Fit\u00f3, M., and Hern\u00e1ez, \u00c1. (2020). High-density lipoprotein characteristics and coronary artery disease: A Mendelian randomization study. Metabolism, 112.","DOI":"10.1016\/j.metabol.2020.154351"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/sj.ejhg.5201467","article-title":"Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia","volume":"13","author":"Jansen","year":"2005","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nrg2809","article-title":"Missing heritability and strategies for finding the underlying causes of complex disease","volume":"11","author":"Eichler","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1567-5688(01)00013-7","article-title":"Environmental modulation of atherosclerosis end points in familial hypercholesterolemia","volume":"2","author":"Hegele","year":"2002","journal-title":"Atheroscler. Suppl."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1161\/ATVBAHA.110.209064","article-title":"Dyslipidemia of mothers with familial hypercholesterolemia deteriorates lipids in adult offspring","volume":"30","author":"Vissers","year":"2010","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"14443","DOI":"10.1074\/jbc.M110270200","article-title":"Identification of sterol-independent regulatory elements in the human ATP-binding cassette transporter A1 promoter: Role of Sp1\/3, E-box binding factors and an oncostatin M-responsive element","volume":"277","author":"Langmann","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4161\/epi.19633","article-title":"ABCA1gene promoter DNA methylation is associated with HDL particle profile and coronary artery disease in familial hypercholesterolemia","volume":"7","author":"Guay","year":"2012","journal-title":"Epigenetics"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.atherosclerosis.2013.03.033","article-title":"DNA methylation variations at CETP and LPL gene promoter loci: New molecular biomarkers associated with blood lipid profile variability","volume":"228","author":"Guay","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2217\/epi.12.62","article-title":"Epigenome-wide analysis in familial hypercholesterolemia identified new loci associated with high-density lipoprotein cholesterol concentration","volume":"4","author":"Guay","year":"2012","journal-title":"Epigenomics"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2217\/epi.15.120","article-title":"Epigenetic and genetic variations at the TNNT1 gene locus are associated with HDL-C levels and coronary artery disease","volume":"8","author":"Guay","year":"2016","journal-title":"Epigenomics"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4161\/epi.27981","article-title":"Epipolymorphisms within lipoprotein genes contribute inde-pendently to plasma lipid levels in familial hypercholesterolemia","volume":"9","author":"Guay","year":"2014","journal-title":"Epigenetics"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/01.ATV.20.9.2113","article-title":"Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients","volume":"20","author":"Vila","year":"2000","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1161\/01.ATV.0000096207.01487.36","article-title":"Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: A role for sterol regulatory element-binding protein-2","volume":"23","author":"Deakin","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1365-2796.2005.01557.x","article-title":"The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia","volume":"258","author":"Tits","year":"2005","journal-title":"J. Intern. Med."},{"key":"ref_76","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolemia","volume":"43","author":"Kastelein","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolemia: (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.jacc.2020.01.033","article-title":"High-density lipoproteins are the main carriers of PCSK9 in the circulation","volume":"75","author":"Burnap","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-511X-10-5","article-title":"The proprotein convertase subtilisin\/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations","volume":"10","author":"Aung","year":"2011","journal-title":"Lipids Health Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trsl.2015.10.004","article-title":"Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: Experimental animal models and clinical evidence","volume":"173","author":"Ferri","year":"2016","journal-title":"Transl. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"30455","DOI":"10.18632\/oncotarget.10762","article-title":"Efficacy and safety of proprotein convertase subtilisin\/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia","volume":"8","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41598-017-00316-3","article-title":"Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials","volume":"7","author":"Qian","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1161\/ATVBAHA.119.313340","article-title":"Proceedings of the ninth HDL (high-density lipoprotein) workshop: Focus on cardiovascular disease","volume":"39","author":"Rodriguez","year":"2019","journal-title":"Arter. Thromb. Vasc. Biol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/7\/810\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:29:52Z","timestamp":1760164192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/7\/810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":87,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["biomedicines9070810"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9070810","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]}}}